The recent success story of twice yearly shots of Lenacapavir preventing HIV in over 96 percent of at-risk people and the Gilead granting royalty-free voluntary licenses to six generic pharma globally ...
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Barchart on MSN20h
Gilead Sciences’ Quarterly Earnings Preview: What You Need to KnowGilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback